Please assess the completion status of the following clinical trial:

Trial Title: Laryngeal Mask Airway (LMA) for Surfactant Administration in Neonates

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Gestational age at time of enrollment 28 0/7 to 35 6/7 weeks postmenstrual age~* Age less than or equal to 36 hours old~* On nCPAP 6 with supplemental oxygen requirement (Fi02 greater than or equal to 30%) for greater than or equal to 30 minutes (to maintain Sa02 between 88-92%)~* Chest radiograph and clinical presentation consistent with respiratory distress syndrome (tachypnea, retractions, nasal flaring, and/or grunting~Exclusion Criteria:~* Prior mechanical ventilation or surfactant administration~* Major congenital anomaly~* Abnormality of the airway~* Respiratory distress secondary to an etiology other than respiratory distress syndrome (pneumothorax, meconium aspiration syndrome, pneumonia, hypoxic-ischemic encephalopathy)~* Apgar score \< 5 at 5 minutes of age

- Gender: ALL
- Minimum Age: None
- Maximum Age: 36 Hours
- Healthy Volunteers: f

Study Arms:
- nCPAP Control Group (Type: ACTIVE_COMPARATOR): Infants in the Control Group were maintained continuously on nasal CPAP 6 cm H2O with no surfactant administered.
- LMA Group (Type: EXPERIMENTAL): Once proper placement of the LMA was achieved, surfactant (Curosurf®, 2.5 ml/kg, Chiesi USA, Inc., Cary, NC) was administered. The LMA cuff was then deflated, LMA removed and the infant placed back on nasal CPAP 6 cm H2O.

Based on this trial design, predict the completion outcome and termination type (if applicable).